国际肿瘤学杂志››2021,Vol. 48››Issue (1): 35-40.doi:10.3760/cma.j.cn371439-20200527-00006
于明月1,2, 陈峥峥3, 赵旭旭3, 任萍萍3, 张影3, 葛丽4, 朱美玲3, 赵卫东1,2,3()
收稿日期:
2020-05-27修回日期:
2020-09-30出版日期:
2021-01-08发布日期:
2021-01-21通讯作者:
赵卫东 E-mail:victorzhao@163.comYu Mingyue1,2, Chen Zhengzheng3, Zhao Xuxu3, Ren Pingping3, Zhang Ying3, Ge Li4, Zhu Meiling3, Zhao Weidong1,2,3()
Received:
2020-05-27Revised:
2020-09-30Online:
2021-01-08Published:
2021-01-21Contact:
Zhao Weidong E-mail:victorzhao@163.com摘要:
目的探讨ⅠB1~ⅡA2期[按2018年国际妇产科联盟(FIGO)分期标准]宫颈癌术后辅助治疗的相关影响因素,建立个体化预测局部晚期宫颈癌术后辅助治疗风险的列线图模型。方法以2009年1月至2019年12月于安徽省立医院行手术治疗的ⅠB1~ⅡA2期宫颈鳞状细胞癌患者714例为研究对象,分析其临床病理资料。采用多因素logistic回归分析宫颈癌术后辅助治疗的影响因素,并建立预测宫颈癌术后辅助治疗风险的列线图模型,用一致性系数(C-index)评估模型的预测性能,校准曲线评估模型的符合度。结果单因素分析提示,宫颈癌术后辅助治疗与患者的孕次(χ2=11.506,P=0.001)、是否合并基础疾病(高血压或糖尿病)(χ2=7.668,P=0.006)、鳞状细胞癌抗原(SCC-Ag)水平(χ2=19.392,P<0.001)、影像学检查是否伴有危险因素(χ2=16.392,P<0.001)、FIGO分期(χ2=25.686,P<0.001)、肿瘤大小(χ2=9.392,P=0.025)和手术路径(χ2=16.590,P<0.001)有关。多因素分析提示,孕次>2次(OR=1.951,95%CI为1.355~2.808,P<0.001)、SCC-Ag≥1.5 μg/L(OR=2.021,95%CI为1.444~2.829,P<0.001)、FIGO分期为ⅠB3~ⅡA2期(ⅠB3期:OR=1.933,95%CI为1.139~3.282,P=0.015;ⅡA1期:OR=2.723,95%CI为1.556~4.765,P<0.001;ⅡA2期:OR=3.159,95%CI为1.502~6.646,P=0.002)、合并基础疾病(高血压或糖尿病)(OR=1.867,95%CI为1.051~3.318,P=0.033)、影像学检查伴有危险因素(OR=1.997,95%CI为1.127~3.537,P=0.018)、未行新辅助治疗(术前行辅助治疗1疗程:OR=0.402,95%CI为0.207~0.783,P=0.007)、行腹腔镜手术(OR=2.177,95%CI为1.524~3.112,P<0.001)为宫颈癌术后追加辅助治疗的独立影响因素。根据筛选出的变量所构建的预测宫颈癌术后辅助治疗风险的列线图模型具有较好的预测性能(C-index为0.702)和符合度。结论孕次>2次、SCC-Ag≥1.5 μg/L、FIGO分期为ⅠB3~ⅡA2期、合并基础疾病(高血压或糖尿病)、影像学检查伴有危险因素、未行新辅助治疗、行腹腔镜手术为宫颈癌术后追加辅助治疗的独立影响因素,构建了可用于预测局部晚期宫颈癌术后辅助治疗风险的列线图模型,可为临床治疗选择提供依据。
于明月, 陈峥峥, 赵旭旭, 任萍萍, 张影, 葛丽, 朱美玲, 赵卫东. 局部晚期宫颈癌术后辅助治疗的影响因素及其列线图风险模型的构建[J]. 国际肿瘤学杂志, 2021, 48(1): 35-40.
Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong. Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model[J]. Journal of International Oncology, 2021, 48(1): 35-40.
表1
宫颈癌患者术后辅助治疗的单因素分析(例)"
因素 | 未辅助治疗组 (n=441) |
辅助治疗组 (n=273) |
χ2值 | P值 | |||
---|---|---|---|---|---|---|---|
年龄(岁) | |||||||
≤35 | 39 | 24 | 0.001 | 0.981 | |||
>35 | 402 | 249 | |||||
初潮年龄(岁)a | |||||||
<14 | 91 | 59 | 0.229 | 0.632 | |||
≥14 | 306 | 181 | |||||
因素 | 未辅助治疗组 (n=441) |
辅助治疗组 (n=273) |
χ2值 | P值 | |||
孕次 | |||||||
≤2次 | 162 | 67 | 11.506 | 0.001 | |||
>2次 | 279 | 206 | |||||
产次 | |||||||
≤2次 | 342 | 195 | 3.390 | 0.066 | |||
>2次 | 99 | 78 | |||||
是否合并基础疾病 (高血压或糖尿病) |
|||||||
是 | 26 | 32 | 7.668 | 0.006 | |||
否 | 415 | 241 | |||||
SCC-Ag(μg/L) | |||||||
<1.5 | 246 | 106 | 19.392 | <0.001 | |||
≥1.5 | 195 | 167 | |||||
血红蛋白(g/L) | |||||||
<110 | 112 | 64 | 0.346 | 0.556 | |||
≥110 | 329 | 209 | |||||
影像学检查是否 伴有危险因素 |
|||||||
有 | 24 | 39 | 16.392 | <0.001 | |||
无 | 417 | 234 | |||||
FIGO分期 | |||||||
ⅠB1 | 121 | 50 | |||||
ⅠB2 | 180 | 89 | |||||
ⅠB3 | 73 | 55 | 25.686 | <0.001 | |||
ⅡA1 | 43 | 50 | |||||
ⅡA2 | 24 | 29 | |||||
肿瘤大小(cm) | |||||||
<2 | 128 | 58 | |||||
≥2且<4 | 216 | 131 | 9.392 | 0.025 | |||
≥4且<5 | 65 | 53 | |||||
≥5 | 32 | 31 | |||||
组织学分化程度 | |||||||
高分化(G1) | 14 | 9 | |||||
中分化(G2) | 283 | 178 | 0.105 | 0.949 | |||
低分化(G3) | 144 | 86 | |||||
术前新辅助化疗的 疗程数 |
|||||||
0 | 387 | 247 | |||||
1 | 40 | 19 | 1.263 | 0.532 | |||
2 | 14 | 7 | |||||
手术路径 | |||||||
开腹 | 179 | 70 | 16.590 | <0.001 | |||
腹腔镜 | 262 | 203 |
表2
714例宫颈癌患者术后辅助治疗的多因素分析"
变量 | β值 | SE值 | Wald值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
孕次(>2次) | 0.668 | 0.186 | 12.917 | <0.001 | 1.951 | 1.355~2.808 |
SCC-Ag(≥1.5 μg/L) | 0.704 | 0.172 | 16.809 | <0.001 | 2.021 | 1.444~2.829 |
FIGO分期 | 20.942 | <0.001 | ||||
ⅠB1 | ||||||
ⅠB2 | 0.153 | 0.223 | 0.471 | 0.492 | 1.166 | 0.752~1.806 |
ⅠB3 | 0.659 | 0.270 | 5.960 | 0.015 | 1.933 | 1.139~3.282 |
ⅡA1 | 1.002 | 0.286 | 12.312 | <0.001 | 2.723 | 1.556~4.765 |
ⅡA2 | 1.150 | 0.379 | 9.914 | 0.002 | 3.159 | 1.502~6.646 |
是否合并基础疾病(是) | 0.624 | 0.293 | 4.529 | 0.033 | 1.867 | 1.051~3.318 |
影像学检查是否伴有危险因素(是) | 0.691 | 0.292 | 5.616 | 0.018 | 1.997 | 1.127~3.537 |
术前行辅助化疗的疗程数 | 7.735 | 0.021 | ||||
0 | ||||||
1 | -0.910 | 0.340 | 7.184 | 0.007 | 0.402 | 0.207~0.783 |
2 | -0.567 | 0.515 | 1.212 | 0.271 | 0.567 | 0.207~1.556 |
手术路径(腹腔镜) | 0.778 | 0.182 | 18.242 | <0.001 | 2.177 | 1.524~3.112 |
[1] | Bray F, Ferla J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.21492pmid:30207593 |
[2] | Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338. pmid:26808342 |
[3] | Suh DH, Kim M, Kim K, et al. Major clinical research advances in gynecologic cancer in 2016: 10-year special edition[J]. J Gynecol Oncol, 2017,28(3):e45. DOI: 10.3802/jgo.2017.28.e45. doi:10.3802/jgo.2017.28.e45pmid:28382802 |
[4] | Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage ⅠB2, ⅡA, or ⅡB squamous cervical cancer: a randomized controlled trial[J]. J Clin Oncol, 2018,36(16):1548-1555. DOI: 10.1200/JCO.2017.75.9985. pmid:29432076 |
[5] | Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer[J]. The Lancet, 2019,393(10167):169-182. DOI: 10.1016/s0140-6736(18)32470-x. |
[6] | Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase Ⅲ rando-mised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages ⅠB2, ⅡA2, and ⅡB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)[J]. Br J Cancer, 2013,108(10):1957-1963. DOI: 10.1038/bjc.2013.179. doi:10.1038/bjc.2013.179pmid:23640393 |
[7] | Eddy GL, Bundy BN, Creasman WT, et al. Treatment of (“bulky”) stage ⅠB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lym-phadenectomy: a phase Ⅲ trial of the gynecologic oncology group[J]. Gynecol Oncol, 2007,106(2):362-369. DOI: 10.1016/j.ygyno.2007.04.007. doi:10.1016/j.ygyno.2007.04.007pmid:17493669 |
[8] | 庄金满, 卢婉婷, 黄玉秀, 等. 早期宫颈癌淋巴结转移的高危因素分析及列线图预测模型的构建[J]. 肿瘤防治研究, 2019,46(1):50-54. DOI: 10.3971/j.issn.1000-8578.2019.18.0942. |
[9] | 张宏彦, 占瑾琼, 曹玉广, 等. 中国妇女行为危险因素与子宫颈癌发病关系的Meta分析[J]. 中华肿瘤防治杂志, 2011,18(3):165-169. |
[10] | Al-Madani W, Ahmed AE, Arabi H, et al. Modelling risk assessment for cervical cancer in symptomatic Saudi women[J]. Saudi Med J, 2019,40(5):447-451. DOI: 10.15537/smj.2019.5.24085. pmid:31056620 |
[11] | Chen S, Tao M, Zhao L, et al. The association between diabetes/hyperglycemia and the prognosis of cervical cancer patients: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2017,96(40):e7981. DOI: 10.1097/MD.0000000000007981. |
[12] | Liu Z, Shi H. Prognostic role of squamous cell carcinoma antigen in cervical cancer: a meta-analysis[J]. Dis Markers, 2019,2019:6710352. DOI: 10.1155/2019/6710352. doi:10.1155/2019/6710352pmid:31275450 |
[13] | Choi KH, Lee SW, Yu M, et al. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis[J]. J Gynecol Oncol, 2019,30(1):e1. DOI: 10.3802/jgo.2019.30.e1. doi:10.3802/jgo.2019.30.e1pmid:30479085 |
[14] | Zhou Z, Li W, Zhang F, et al. The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: a meta-analysis and literature review[J]. PLoS One, 2017,12(12):e0186165. DOI: 10.1371/journal.pone.0186165. doi:10.1371/journal.pone.0186165pmid:29227998 |
[15] | Fu J, Wang W, Wang Y, et al. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemo-radiotherapy and treatment decisions for patients with cervical cancer[J]. Radiat Oncol, 2019,14(1):146. DOI: 10.1186/s13014-019-1355-4. doi:10.1186/s13014-019-1355-4pmid:31416463 |
[16] | Mallmann P, Mallmann C. Neoadjuvant and adjuvant chemotherapy of cervical cancer[J]. Oncol Res Treat, 2016,39(9):522-524. DOI: 10.1159/000449023. doi:10.1159/000449023pmid:27614740 |
[17] | Cibula D. A novel perspective of neoadjuvant chemotherapy in locally advanced cervical cancer[J]. Ann Surg Oncol, 2016,23(7):2126-2127. DOI: 10.1245/s10434-015-5000-7. doi:10.1245/s10434-015-5000-7pmid:26603625 |
[18] | Robova H, Halaska M, Pluta M, et al. The role of neoadjuvant chemotherapy and surgery in cervical cancer[J]. Int J Gynecol Cancer, 2010,20(11 Suppl 2):S42-S46. DOI: 10.1111/igc.0b013e3181f60d73. doi:10.1111/igc.0b013e3181f60d73pmid:21053526 |
[19] | Cho YH, Kim DY, Kim JH, et al. Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage ⅠB2-ⅡA bulky cervical cancer[J]. J Gynecol Oncol, 2009,20(1):22-27. DOI: 10.3802/jgo.2009.20.1.22. doi:10.3802/jgo.2009.20.1.22pmid:19471665 |
[20] | Zhao H, He Y, Zhu LR, et al. Effect of neoadjuvant chemotherapy followed by radical surgery for FIGO stage ⅠB2/ⅡA2 cervical can-cer: a multi-center retrospective clinical study[J]. Medicine (Baltimore), 2019,98(21):e15604. DOI: 10.1097/MD.00000-00000015604. doi:10.1097/MD.0000000000015604 |
[21] | Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J]. Cochrane Database Syst Rev, 2012, 12(12): CD007406. DOI: 10.1002/14651858.CD007406.pub3. |
[22] | Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer[J]. N Engl J Med, 2018,379(20):1895-1904. DOI: 10.1056/NEJMoa1806395. doi:10.1056/NEJMoa1806395pmid:30380365 |
[23] | Wang W, Li L, Wu M, et al. Laparoscopic vs. abdominal radical hysterectomy for locally advanced cervical cancer[J]. Front Oncol, 2019,9:1331. DOI: 10.3389/fonc.2019.01331. doi:10.3389/fonc.2019.01331pmid:31828044 |
[1] | 张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291. |
[2] | 孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150. |
[3] | 陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82. |
[4] | 王潇, 李盈, 罗玉杰, 晋舒.基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469. |
[5] | 张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英.免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483. |
[6] | 吕璐, 孙鹏飞.肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376. |
[7] | 段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏.复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768. |
[8] | 马雪艳, 鲁历历, 孙鹏飞.免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50. |
[9] | 张露, 周菊英, 马辰莺, 林州.复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520. |
[10] | 史英侠, 胡莉钧, 于静萍.免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571. |
[11] | 彭琛, 谢印通, 张昕, 谢鹏.宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435. |
[12] | 熊婵, 阎英, 谢晓冬, 孟繁杰, 于卉影.辐射诱导的多倍体宫颈癌HeLa细胞生物学特性研究[J]. 国际肿瘤学杂志, 2022, 49(5): 263-269. |
[13] | 袁晨阳, 周菊英.宫颈癌预后因素的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 307-313. |
[14] | 袁晨阳, 周菊英, 杜霄, 纪环, 赵天翼.宫颈癌2018与2009 FIGO分期的比较及预后因素分析[J]. 国际肿瘤学杂志, 2022, 49(3): 151-163. |
[15] | 王玥, 吴琼, 许愿, 龚唯, 徐晓婷.老年宫颈癌的筛查与治疗进展[J]. 国际肿瘤学杂志, 2022, 49(12): 754-758. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||